Relay Medical Reports on Technical Advancement of HemoPalm System
May 14, 2019 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), an engine of MedTech innovation, is pleased to report on technical advances of the Company’s enhanced HemoPalm point-of-care (POC) testing platform.
· Demonstrated feasibility of whole blood analysis: The Company’s proprietary optical approach has demonstrated accurate measurement of hemoglobin fractions (compared with industry-leading benchtop CO-oximetry analyzer) without red blood cell hemolysis. Relay’s CO-oximetry measurement technology enables the direct measurement of whole blood samples, without the need for red blood cell hemolysis as typically required in larger, more complex benchtop systems.
· Decoupled CO-oximetry optical chamber from unit-use cartridge for cost, precision, and commercial optionality: The separation of components allows flexibility for material selection and manufacturing methods to optimize performance and production yields. Additionally, the decoupling provides commercial flexibility, allowing for Relay’s proprietary CO-oximetry measurement technology to be licensed to strategic partners and integrated into existing diagnostic platforms.
· Demonstrated feasibility of advanced third-generation microfluidic cartridge: A new, simplified cartridge design that supports more robust operation and cost-efficient manufacturing has demonstrated reliable, controlled fluid flows through a series of microfluidic tests. The third-generation cartridge includes a novel integrated calibration fluid module and design compatible with cost-efficient manufacturing processes.
Relay’s current focus is on refining key proprietary system components to ensure optimization of assay accuracy, manufacturability, and cost – design criteria critical to competitive advantage and integration with strategic partners.
“Relay has made significant progress in demonstrating the viability of our proprietary CO-oximetry technology and optimizing the design for cost effective reproducibility and integration with standard manufacturing practices. Our ability to make measurements directly in whole blood is a significant simplification of the system that will reduce cartridge and instrument costs and improve reliability.” said Paul Glavina, Vice President, In Vitro Diagnostics, Relay Medical Corp.
“Cost and performance are of the utmost importance when commercializing a technology to address the point-of-care in vitro diagnostic market. Our proprietary CO-oximetry measurement technology and redesigned cartridge, alone or coupled with blood gas biosensor technologies, address clear menu gaps in the point-of-care marketplace. We are very pleased to share these critical advancements that move us closer to delivering pre-commercial exits of Relay technology.” said Lahav Gil, CEO, Relay Medical Corp.
Experiments with bovine whole blood, using Relay’s latest algorithms, have successfully demonstrated accurate measurement (as measured against an industry-leading benchtop CO-oximetry analyzer) of the various hemoglobin fractions required for the CO-oximetry test panel. The direct measurement of whole blood simplifies the cartridge design and fluidics, and ultimately reduces the cost and increases the reliability of the CO-oximetry measurements.
Relay has recently designed an optical flow-through CO-oximetry cell sub-assembly (an optical cuvette) that inserts into the unit-use microfluidic cartridge. These cuvettes are designed for reproducible, high-volume and low-cost manufacturability.
Development of Relay’s microfluidic cartridge that combines the optical CO-oximetry tests with electrochemical blood gas and electrolyte biosensors has also advanced. A third-generation cartridge design incorporates a novel calibration fluid reservoir that allows for precise and controlled delivery of calibrator fluid. The design has undergone a series of successful fluidic tests to demonstrate robust calibration fluid actuation, as well as sample aspiration, valving, bubble trapping, waste collection and venting. Automated test fixtures and associated custom software are being developed to accelerate the cartridge development program.
Relay’s HemoPalm system is being developed as a complete healthcare-enterprise solution for blood gas, electrolyte, and CO-oximetry testing. Utilizing a disposable, unit-use cartridge and handheld reader, it improves the cost, quality, timeliness, and efficiency of patient care.
About Relay Medical Corp.
Relay Medical is an evolving “Integrated MedTech Accelerator” headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay Medical is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.
W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
EU Investor Relations
Office. +49 (0) 177 774 2314
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the HemoPalm product described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com